Most GLP-1 price tables get longer as the dose rises. Wegovy's does not: Novo Nordisk charges the same $349 a month for the starting dose and the maintenance dose and every step between them. That single decision makes Wegovy the easiest GLP-1 to budget for and the hardest to compare with anything else.
It is also the harder of the manufacturer's two semaglutide brands to keep straight, because both Wegovy and Ozempic now sell an injection and a tablet and the approved uses differ within each brand as well as between them (Wegovy's four uses, form by form).
Every figure below comes from Novo Nordisk's Wegovy price guide, document code US26NC00049 dated April 2026, downloaded and read on 2026-09-08, together with the savings-offer page carrying the card's terms. This page reports prices, not treatment decisions; those belong with a prescriber, as our editorial standards explain.
The published self-pay prices
| Form | Dose | Self-pay per month | Terms |
|---|---|---|---|
| Pen | 0.25 mg, 0.5 mg | $199 | New patients only, first two monthly fills, through 2026-12-31 |
| Pen | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg | $349 | Standard offer — one price for the whole ladder |
| HD pen | 7.2 mg | $399 | Standard offer |
| Pill | 1.5 mg | $149 | Standard offer |
| Pill | 4 mg | $199 | Standard offer |
| Pill | 9 mg, 25 mg | $299 | Standard offer |
One month is one box of four pens, or one bottle of 30 tablets. The pens are single-dose; four of them cover four weekly injections.
The flat ladder, and why it is unusual
Titration is the normal experience of starting one of these drugs: four weeks at 0.25 mg, four at 0.5 mg, and so on upward. On most price schedules that journey costs more each time it steps.
On Wegovy's it does not. $349 covers 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg alike — a nearly tenfold range of weekly dose at one price. The only increase anywhere in the injectable line is the HD pen at 7.2 mg, which is $399, a $50 step.
Two consequences worth stating. For a patient, the monthly figure after the introductory offer does not move, which makes a year of treatment arithmetically simple in a way this market rarely is: twelve fills at $349 is $4,188, wherever the dose settles. And for anyone comparing brands, the flat ladder is why Wegovy ends up cheaper than Ozempic at the top and identical to it lower down — the divergence is entirely a step in Ozempic's schedule, not a discount in Wegovy's. Our Ozempic cost page sets that comparison out per milligram; the short version is that the higher weekly dose of the same molecule is the cheaper one, by $150 a month.
The $25 that is usually not $25
Novo's card carries the same headline as every other GLP-1 card and the same arithmetic underneath it. It also depends on a plan that covers Wegovy; on CVS Caremark's standard commercial formularies Wegovy has been the preferred GLP-1 since 1 July 2025 — Caremark's GLP-1 coverage, dated.
The footnote, verbatim: "Pay as little as $25, subject to a maximum savings of $100/month." Those are two facts, and only one of them is in large type. (The card's full conditions — the 2- and 3-month caps, the tablet month, the accumulator clause — are read clause by clause on the Wegovy savings card terms.) The card contributes at most $100. So:
- Copay $125 → card pays $100 → patient pays $25. The headline holds.
- Copay $250 → card pays $100 → patient pays $150.
- Copay $500 → card pays $100 → patient pays $400.
The break-even is a $125 copay, which is the same ceiling Zepbound's card produces and $50 below Mounjaro's. Government beneficiaries are excluded from all of them.
One structural difference is worth recording, because it cuts in Novo's favour and is easy to miss. Lilly's cards for Zepbound and Mounjaro publish an annual maximum saving and a limit of 13 fills per calendar year alongside the monthly cap. The Novo footnote we read on 2026-09-08 publishes a monthly cap and neither of the others. We are not claiming no annual limit exists in the full terms — only that the footnote a patient actually reads does not state one, while its Lilly equivalents do.
The Medicare route only this brand has
Wegovy is the semaglutide brand that reaches the Medicare GLP-1 Bridge, under which eligible Part D beneficiaries pay $50 a month. The Bridge runs from 2026-07-01 to 2027-12-31, Novo's page states that the $50 applies to all Wegovy dose strengths, and Part D sponsors do not have to opt in for an eligible beneficiary to use it. Eligibility rests on a prescriber attesting that the drug is for weight reduction and maintenance in an adult meeting one of several BMI-and-diagnosis categories.
That is a $299-a-month difference from the self-pay price for anyone who qualifies, and it is the largest single price gap anywhere in this product's schedule. The policy background — including the separate BALANCE model, which CMS announced on 2026-04-21 it would not run in Part D for 2027 — is on our GLP-1 cost page.
Wegovy also holds a second route into coverage that has nothing to do with the Bridge, and it comes from its own label: its approved cardiovascular indication is not a weight-loss use, which is the distinction the exclusion statute actually turns on.
The packaging trap
A month of Wegovy is a box of four pens. A month of Ozempic is a box of one. Both are four weekly doses; Wegovy's pens are single-dose devices and Ozempic's is multi-dose.
This is worth knowing before comparing anything. A reader who sees "four pens for $349" against "one pen for $349" and concludes that Wegovy supplies four times the drug has been misled by packaging, not by price. The correct comparison is per month, or per weekly dose, and on either basis the two are identical below 2 mg.
What the price is not
$349 is not Wegovy's list price. That figure, quoted by the White House on 2026-02-05, is $1,349 a month, and TrumpRx.gov shows $1,349.02. A list price is what the manufacturer charges wholesalers before rebates and programmes; the self-pay schedule above exists so that a cash-paying patient does not meet it. It still matters to one group: people whose insurance deductible is charged at something close to list before coverage begins. For them the date to note is 2027-01-01: Novo Nordisk announced on 2026-02-24 that Wegovy's list price for the 2.4 mg injection and the 25 mg tablet falls to $675 a month from then, a cut it put at about 50%. The same release says self-pay prices are not affected. Until that date $1,349 is the current list price (re-checked 2026-09-28).
$349 is also not directly comparable to the headline figure on the brand it is most often set against. Zepbound's published self-pay price moves with strength where this one does not, so the cheaper brand depends on where a strength settles — the arithmetic is on our Zepbound vs Wegovy page.
And $349 is not what the pharmacy counter will necessarily say. The guide describes these as prices available through the savings offer or NovoCare Pharmacy — a patient who walks in without the offer applied is not quoted them. Who actually dispenses a NovoCare order, and the self-pay rules in its terms, are set out on how NovoCare Pharmacy works.
Nor is a price the whole of what a prescription costs a person. Wegovy's own label counts hair loss as an adverse reaction at 3% against 1% on placebo, while the Ozempic label for the same molecule does not count it at all — a discrepancy we take apart on our page about where hair loss appears in these labels and where it does not.
Sources, with dates
- Novo Nordisk, Wegovy price guide, document code US26NC00049, dated April 2026 — read 2026-09-08. Every Wegovy price and term on this page comes from it.
- Novo Nordisk, Wegovy savings offer and save on Wegovy — read 2026-09-08, for the card's cap wording.
- Novo Nordisk, Ozempic pill and pen price guide, document code US26NC00009, dated May 2026 — read 2026-09-08, for the comparison figures.
Prices in this market changed four times in the twelve months to September 2026. Every figure here carries the date it was read; re-check the manufacturer page before relying on any of them.
The manufacturer's price is only one of the routes to this medicine, and the others are structured differently enough that the monthly figures are not directly comparable. A membership fee that excludes the drug entirely, as WeightWatchers charges, is not the same kind of number as one that includes a compounded preparation, as Noom's does — and neither is what a warehouse-club membership buys, which turns out not to include a GLP-1 benefit. Where a service splits a membership from the medicine, the two halves have to be added before any comparison means anything; that arithmetic is worked through for one such provider.
One route sells this medicine at exactly the prices above, because Novo Nordisk sets them and the telehealth company only adds its own fee on top: the Ro pricing page documents the multi-month subscription ladder that takes the pen to $249 a month, and the prepayment it requires to get there.